HRP20150340T1 - Konjugati oligosaharid-protein - Google Patents
Konjugati oligosaharid-protein Download PDFInfo
- Publication number
- HRP20150340T1 HRP20150340T1 HRP20150340TT HRP20150340T HRP20150340T1 HR P20150340 T1 HRP20150340 T1 HR P20150340T1 HR P20150340T T HRP20150340T T HR P20150340TT HR P20150340 T HRP20150340 T HR P20150340T HR P20150340 T1 HRP20150340 T1 HR P20150340T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- formula
- fluoride
- image
- hydroxyl
- Prior art date
Links
- 238000000034 method Methods 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000006239 protecting group Chemical group 0.000 claims 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- -1 hydrazide Substances 0.000 claims 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 2
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 claims 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical group [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- PQXKHYXIUOZZFA-UHFFFAOYSA-M lithium fluoride Chemical compound [Li+].[F-] PQXKHYXIUOZZFA-UHFFFAOYSA-M 0.000 claims 2
- 229910001512 metal fluoride Inorganic materials 0.000 claims 2
- 229910001507 metal halide Inorganic materials 0.000 claims 2
- 150000005309 metal halides Chemical class 0.000 claims 2
- 229920001542 oligosaccharide Polymers 0.000 claims 2
- 150000002482 oligosaccharides Chemical class 0.000 claims 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 claims 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- DGIYKLWEVUSOLJ-FPCALVHFSA-N (2s,3r,4r,5r)-2,5-dihydroxy-3,4,6-tris(phenylmethoxy)hexanal Chemical compound C([C@@H](O)[C@@H](OCC=1C=CC=CC=1)[C@H](OCC=1C=CC=CC=1)[C@H](O)C=O)OCC1=CC=CC=C1 DGIYKLWEVUSOLJ-FPCALVHFSA-N 0.000 claims 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 claims 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 claims 1
- 229910001634 calcium fluoride Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002951 idosyl group Chemical class C1([C@@H](O)[C@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims 1
- ORUIBWPALBXDOA-UHFFFAOYSA-L magnesium fluoride Chemical compound [F-].[F-].[Mg+2] ORUIBWPALBXDOA-UHFFFAOYSA-L 0.000 claims 1
- 229910001635 magnesium fluoride Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- QAWFLJGZSZIZHO-UHFFFAOYSA-N methyl 4-bromobutanoate Chemical compound COC(=O)CCCBr QAWFLJGZSZIZHO-UHFFFAOYSA-N 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 235000003270 potassium fluoride Nutrition 0.000 claims 1
- 239000011698 potassium fluoride Substances 0.000 claims 1
- 235000013024 sodium fluoride Nutrition 0.000 claims 1
- 239000011775 sodium fluoride Substances 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical group [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12285108P | 2008-12-16 | 2008-12-16 | |
| EP12160009.2A EP2465542B1 (en) | 2008-12-16 | 2009-12-11 | Oligosaccharide-protein conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150340T1 true HRP20150340T1 (hr) | 2015-07-31 |
Family
ID=42138937
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150340TT HRP20150340T1 (hr) | 2008-12-16 | 2015-03-25 | Konjugati oligosaharid-protein |
| HRP20191102TT HRP20191102T1 (hr) | 2008-12-16 | 2019-06-18 | Sintetski međuprodukti za pripravu konjugata oligosaharid-protein |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191102TT HRP20191102T1 (hr) | 2008-12-16 | 2019-06-18 | Sintetski međuprodukti za pripravu konjugata oligosaharid-protein |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US8835614B2 (enExample) |
| EP (5) | EP2889043B1 (enExample) |
| JP (6) | JP5658167B2 (enExample) |
| CN (5) | CN102369023A (enExample) |
| BR (2) | BR122020010601B8 (enExample) |
| CA (2) | CA3040973A1 (enExample) |
| CY (1) | CY1121860T1 (enExample) |
| DK (3) | DK2889043T3 (enExample) |
| ES (3) | ES2534056T3 (enExample) |
| HR (2) | HRP20150340T1 (enExample) |
| HU (2) | HUE044381T2 (enExample) |
| IL (5) | IL213595B (enExample) |
| LT (1) | LT2889043T (enExample) |
| MX (3) | MX364498B (enExample) |
| PL (2) | PL2889043T3 (enExample) |
| PT (2) | PT2889043T (enExample) |
| SI (2) | SI2889043T1 (enExample) |
| SM (2) | SMT201900375T1 (enExample) |
| TR (1) | TR201909909T4 (enExample) |
| WO (1) | WO2010075010A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| PT2457919T (pt) * | 2007-01-18 | 2019-09-20 | Genzyme Corp | Oligossacáridos compreendendo um grupo amino-oxi e os seus conjugados |
| BR122020010601B8 (pt) | 2008-12-16 | 2021-07-27 | Genzyme Corp | conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas |
| KR102094253B1 (ko) | 2009-08-28 | 2020-03-31 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법 |
| PE20140617A1 (es) | 2011-04-22 | 2014-05-28 | Genzyme Corp | Alfa glucosidasa acida modificada con procesamiento acelerado |
| WO2013096899A2 (en) * | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| WO2013176239A1 (ja) * | 2012-05-24 | 2013-11-28 | 国立大学法人 東京大学 | 酸化オリゴ糖で架橋したゲル材料 |
| DK3201320T5 (da) * | 2014-09-30 | 2024-10-14 | Amicus Therapeutics Inc | Højpotent sur alfa-glucosidase med forbedrede carbohydrater |
| EP3271453B1 (en) | 2015-03-17 | 2021-09-08 | eleva GmbH | Glycosylated lysosomal proteins, method of production and uses |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| MX394968B (es) | 2015-12-30 | 2025-03-24 | Amicus Therapeutics Inc | Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe. |
| CA3019128A1 (en) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
| KR102343162B1 (ko) | 2016-03-30 | 2021-12-23 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 고 m6p 재조합 단백질의 선택 방법 |
| WO2017170896A1 (ja) * | 2016-03-30 | 2017-10-05 | 国立大学法人徳島大学 | マンノース－６－リン酸基含有糖蛋白質の製造方法、及び蛍光基結合型マンノース－６－リン酸基含有糖蛋白質の細胞内分布を検出する方法 |
| EP3439704A1 (en) * | 2016-04-05 | 2019-02-13 | GSK Vaccines S.r.l. | Immunogenic compositions |
| CN106432371A (zh) * | 2016-10-31 | 2017-02-22 | 中国人民解放军第二军医大学 | β‑1,2‑D‑寡聚甘露糖蛋白缀合物及其制备方法和应用 |
| CN106366163A (zh) * | 2016-10-31 | 2017-02-01 | 中国人民解放军第二军医大学 | 一种β‑1,2‑D‑寡聚甘露糖肽‑蛋白缀合物及其制备方法和应用 |
| SMT202300187T1 (it) | 2017-05-15 | 2023-07-20 | Amicus Therapeutics Inc | Alfa-glucosidasi acida umana ricombinante |
| CA3105823C (en) | 2018-07-09 | 2023-07-25 | Merck Sharp & Dohme Corp. | Enzymatic synthesis of 4'-ethynyl nucleoside analogs |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| JP2021533200A (ja) | 2018-08-02 | 2021-12-02 | ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. | 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| MX2021007376A (es) * | 2018-12-19 | 2021-09-21 | Univ Leland Stanford Junior | Moléculas bifuncionales para el direccionamiento lisosómico y composiciones y métodos relacionados. |
| EP4100120A1 (en) * | 2020-02-08 | 2022-12-14 | Genzyme Corporation | Compositions and methods for treating pompe disease |
| JP2023530112A (ja) * | 2020-06-14 | 2023-07-13 | ジェンザイム・コーポレーション | 遅発型ポンペ病を処置するための組成物及び方法 |
| WO2023288033A1 (en) | 2021-07-14 | 2023-01-19 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4701521A (en) | 1978-07-17 | 1987-10-20 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
| US4749570A (en) | 1981-12-31 | 1988-06-07 | The Governors Of The University Of Alberta | Targeting conjugates of albumin and therapeutic agents |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| JPS5936691A (ja) * | 1982-08-24 | 1984-02-28 | Rikagaku Kenkyusho | 新規オリゴマンノシド及びその製造法 |
| US5851991A (en) | 1987-08-31 | 1998-12-22 | The Regents Of The University Of California | Therapeutic use of the retinoblastoma susceptibility gene product |
| US5066789A (en) | 1988-09-30 | 1991-11-19 | Neorx Corporation | Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
| IL93432A (en) | 1989-02-24 | 1994-02-27 | Johnson Mathey Inc | Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions |
| US5206370A (en) | 1989-02-24 | 1993-04-27 | Johnson Matthey, Inc. | Certain pyridyl hydrazines and hydrazides useful for protein labeling |
| US5179023A (en) | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
| US5212298A (en) | 1989-08-16 | 1993-05-18 | Monsanto Company | Method for producing synthetic N-linked glycoconjugates |
| US5280113A (en) | 1989-08-16 | 1994-01-18 | Monsanto Company | Method for producing synthetic N-linked glycoconjugates |
| US5324663A (en) | 1990-02-14 | 1994-06-28 | The Regents Of The University Of Michigan | Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5583042A (en) | 1990-04-16 | 1996-12-10 | Neose Pharmaceuticals, Inc. | Apparatus for the synthesis of saccharide compositions |
| US5312903A (en) * | 1990-06-01 | 1994-05-17 | E. I. Du Pont De Nemours And Company | Lysine-glycosylated recombinant interleukin-2 |
| US5677440A (en) | 1990-07-16 | 1997-10-14 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates |
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| EP0513332A4 (en) | 1990-11-14 | 1993-03-17 | Cargill, Incorporated | Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins |
| CA2101918A1 (en) | 1991-03-18 | 1992-09-19 | Samuel Zalipsky | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| ATE227583T1 (de) * | 1991-12-20 | 2002-11-15 | Novo Nordisk As | Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US6372716B1 (en) * | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
| FR2721612B1 (fr) | 1994-06-23 | 1996-08-09 | Idm | Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications. |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| US5948767A (en) | 1994-12-09 | 1999-09-07 | Genzyme Corporation | Cationic amphiphile/DNA complexes |
| US5767099A (en) | 1994-12-09 | 1998-06-16 | Genzyme Corporation | Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules |
| US5719131A (en) | 1994-12-09 | 1998-02-17 | Genzyme Corporation | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
| US5650096A (en) | 1994-12-09 | 1997-07-22 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
| US5939401A (en) | 1994-12-09 | 1999-08-17 | Genzyme Corporation | Cationic amphiphile compositions for intracellular delivery of therapeutic molecules |
| US5910487A (en) | 1994-12-09 | 1999-06-08 | Genzyme Corporation | Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
| US5747471A (en) | 1994-12-09 | 1998-05-05 | Genzyme Corporation | Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US6492332B1 (en) | 1995-12-12 | 2002-12-10 | Omeros Corporation | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation |
| US5811510A (en) | 1995-04-14 | 1998-09-22 | General Hospital Corporation | Biodegradable polyacetal polymers and methods for their formation and use |
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| US6632670B1 (en) | 1995-09-08 | 2003-10-14 | Genzyme Corporation | AAV vectors for gene therapy |
| WO1997010817A1 (en) | 1995-09-20 | 1997-03-27 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US7141676B1 (en) | 1996-02-08 | 2006-11-28 | University Of Washington | Water soluble multi-biotin-containing compounds |
| AU2341197A (en) * | 1996-03-21 | 1997-10-10 | Intercardia, Inc. | Solid phase lipoglycopeptide library, compositions and methods |
| US5840702A (en) | 1996-03-22 | 1998-11-24 | Uab Research Foundation | Cystic fibrosis treatment |
| US5935936A (en) | 1996-06-03 | 1999-08-10 | Genzyme Corporation | Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules |
| AUPO190596A0 (en) | 1996-08-26 | 1996-09-19 | Alchemia Pty Ltd | Oligosaccharide synthesis |
| DE69732129T2 (de) | 1996-09-13 | 2005-12-08 | Transkaryotic Therapies, Inc., Cambridge | THERAPIE FÜR alpha GALACTOSIDASE A INSUFFIZIENZ |
| US5861397A (en) | 1996-10-03 | 1999-01-19 | Vical Incorporated | Piperazine based cytofectins |
| AU722315B2 (en) | 1997-01-21 | 2000-07-27 | Pasteur Merieux Serums Et Vaccins | Polysaccharide-peptide conjugates |
| US5925628A (en) | 1997-03-31 | 1999-07-20 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
| US5912239A (en) | 1997-04-04 | 1999-06-15 | Genzyme Corporation | Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules |
| US5948925A (en) | 1997-05-06 | 1999-09-07 | Genzyme Corporation | Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids |
| US5952516A (en) | 1997-05-08 | 1999-09-14 | Genzyme Corporation | Cationic amphiphiles containing multiplesteroid lipophilic groups |
| US5942634A (en) | 1997-05-09 | 1999-08-24 | Genzyme Corporation | Cationic amphiphiles for cell transfections |
| EP1027069B1 (en) | 1997-10-29 | 2006-07-26 | Genzyme Corporation | Gene therapy for gaucher disease |
| SE513149C2 (sv) | 1997-12-05 | 2000-07-17 | Katarina Edwards | Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna |
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| US6703488B1 (en) | 1998-01-15 | 2004-03-09 | Center For Molecular Medicine And Immunology | Antibody/receptor targeting moiety for enhanced delivery of armed ligand |
| US6287857B1 (en) | 1998-02-09 | 2001-09-11 | Genzyme Corporation | Nucleic acid delivery vehicles |
| US6303371B1 (en) | 1998-02-17 | 2001-10-16 | Genzyme Corporation | Method of purified rAAV vector production in non-human cell line transfected with cocksackie and adenovirus receptor |
| AU752284B2 (en) | 1998-02-17 | 2002-09-12 | Genzyme Corporation | Methods for pseudoadenoviral vector production |
| US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
| WO1999057296A1 (en) | 1998-05-01 | 1999-11-11 | Genzyme Corporation | Partially deleted adenoviral vectors |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| US6538117B1 (en) | 1999-08-10 | 2003-03-25 | The Scripps Research Institute | Programmable one-pot oligosaccharide synthesis |
| US6399575B1 (en) | 1998-11-10 | 2002-06-04 | Auburn University | Methods and compositions for targeting compounds to the central nervous system |
| US6610703B1 (en) | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
| GB9909064D0 (en) | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| GB0100889D0 (en) | 2001-01-12 | 2001-02-21 | Oxford Glycosciences Uk Ltd | Compounds |
| GB9909066D0 (en) | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| ATE234626T1 (de) | 1999-07-26 | 2003-04-15 | Searle & Co | Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten |
| US6770468B1 (en) | 1999-09-14 | 2004-08-03 | Genzyme Glycobiology Research Institute, Inc. | Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway |
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| ES2284545T3 (es) | 1999-11-16 | 2007-11-16 | Genzyme Corporation | Vectores y transgenes con elementos reguladores para la administracion de genes del higado. |
| AU2001238346A1 (en) | 2000-02-15 | 2001-08-27 | Genzyme Corporation | Modification of biopolymers for improved drug delivery |
| US6749865B2 (en) | 2000-02-15 | 2004-06-15 | Genzyme Corporation | Modification of biopolymers for improved drug delivery |
| WO2001060377A2 (en) | 2000-02-17 | 2001-08-23 | Genzyme Corporation | Methods for treatment of lysosomal storage diseases using biphosphonates |
| WO2002057445A1 (en) | 2000-05-26 | 2002-07-25 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| US20040014652A1 (en) | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20040067527A1 (en) | 2000-07-26 | 2004-04-08 | Sara Lavi | Intracellular delivery system for protein phosphatases and other polypeptides |
| EP1315559B1 (en) | 2000-08-18 | 2006-03-22 | Massachusetts Institute Of Technology | Apparatus and methods for the automated synthesis of oligosaccharides |
| US6676963B1 (en) | 2000-10-27 | 2004-01-13 | Barnes-Jewish Hospital | Ligand-targeted emulsions carrying bioactive agents |
| US7723296B2 (en) * | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| US7001994B2 (en) * | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| ATE384736T1 (de) | 2001-04-30 | 2008-02-15 | Zystor Therapeutics Inc | Subzelluläres targeting von therapeutischen proteinen |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| WO2001090139A2 (en) | 2001-05-07 | 2001-11-29 | Supratek Pharma Inc. | A ligand for enhancing oral and cns delivery of biological agents |
| BR122015016313B8 (pt) | 2001-07-16 | 2021-05-25 | Genzyme Corp | composto semelhante à ceramida e método de preparar um composto |
| US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| ES2561985T3 (es) | 2001-10-10 | 2016-03-01 | Ratiopharm Gmbh | Remodelación y glicoconjugación de anticuerpos |
| US6835831B2 (en) | 2001-11-26 | 2004-12-28 | Genzyme Corporation | Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
| JP2005535280A (ja) * | 2001-11-28 | 2005-11-24 | ネオーズ テクノロジーズ， インコーポレイテッド | エンドグリカナーゼを用いる糖タンパク質のリモデリング |
| US6800472B2 (en) | 2001-12-21 | 2004-10-05 | Genzyme Glycobiology Research Institute, Inc. | Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase |
| US6905856B2 (en) | 2001-12-21 | 2005-06-14 | Genzyme Glycobiology Research Institute, Inc. | Soluble GlcNAc phosphotransferase |
| EP1463512B1 (en) | 2002-01-11 | 2014-05-28 | biOasis Technologies Inc. | Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
| EP2138575B8 (en) | 2002-02-20 | 2013-07-24 | Mersana Therapeutics, Inc. | Conjugates comprising a biodegradable polymer and uses therefor |
| US6916802B2 (en) | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
| WO2004069190A2 (en) | 2003-01-31 | 2004-08-19 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiency disorders |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| CA2525236C (en) | 2003-06-20 | 2015-03-24 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| EP1654004A2 (en) | 2003-08-08 | 2006-05-10 | Novo Nordisk A/S | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides |
| ES2294535T3 (es) | 2003-08-12 | 2008-04-01 | Lipoxen Technologies Limited | Derivados del acido polisialico. |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US7232805B2 (en) | 2003-09-10 | 2007-06-19 | Inflabloc Pharmaceuticals, Inc. | Cobalamin conjugates for anti-tumor therapy |
| EP1525890A1 (en) | 2003-10-02 | 2005-04-27 | Complex Biosystems GmbH | Protein-Proteophore complexes |
| US7176185B2 (en) | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
| WO2005072778A2 (en) | 2004-01-29 | 2005-08-11 | Biosynexus, Inc. | Use of amino-oxy functional groups in the preparation of vaccines conjugates |
| WO2005077093A2 (en) | 2004-02-06 | 2005-08-25 | Biomarin Pharmaceutical Inc. | Manufacture of highly phosphorylated lysosomal enzymes and uses thereof |
| WO2005094874A1 (en) | 2004-04-01 | 2005-10-13 | Zymenex A/S | Medical use of alpha-mannosidase |
| US8017151B2 (en) | 2004-09-07 | 2011-09-13 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Amphiphilic polymer-protein conjugates and methods of use thereof |
| WO2006108052A2 (en) | 2005-04-06 | 2006-10-12 | Genzyme Corporation | Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting |
| AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| US20070249014A1 (en) * | 2006-02-10 | 2007-10-25 | Invitrogen Corporation | Labeling and detection of post translationally modified proteins |
| WO2008089339A2 (en) * | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharide conjugates for cellular targeting |
| PT2457919T (pt) | 2007-01-18 | 2019-09-20 | Genzyme Corp | Oligossacáridos compreendendo um grupo amino-oxi e os seus conjugados |
| BR122020010601B8 (pt) | 2008-12-16 | 2021-07-27 | Genzyme Corp | conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas |
| US12285108B1 (en) | 2024-08-08 | 2025-04-29 | Frank R. Connors | Shelf device with interchangeable faceplate |
-
2009
- 2009-12-11 BR BR122020010601A patent/BR122020010601B8/pt active IP Right Grant
- 2009-12-11 LT LTEP14194176.5T patent/LT2889043T/lt unknown
- 2009-12-11 HU HUE14194176 patent/HUE044381T2/hu unknown
- 2009-12-11 PT PT14194176T patent/PT2889043T/pt unknown
- 2009-12-11 CN CN200980156896XA patent/CN102369023A/zh active Pending
- 2009-12-11 CN CN202011434866.5A patent/CN112618724A/zh active Pending
- 2009-12-11 MX MX2015002855A patent/MX364498B/es unknown
- 2009-12-11 EP EP14194176.5A patent/EP2889043B1/en active Active
- 2009-12-11 CN CN202011052459.8A patent/CN112220930A/zh active Pending
- 2009-12-11 ES ES12160009.2T patent/ES2534056T3/es active Active
- 2009-12-11 WO PCT/US2009/067775 patent/WO2010075010A2/en not_active Ceased
- 2009-12-11 EP EP12160009.2A patent/EP2465542B1/en active Active
- 2009-12-11 DK DK14194176.5T patent/DK2889043T3/da active
- 2009-12-11 TR TR2019/09909T patent/TR201909909T4/tr unknown
- 2009-12-11 CA CA3040973A patent/CA3040973A1/en not_active Abandoned
- 2009-12-11 PL PL14194176T patent/PL2889043T3/pl unknown
- 2009-12-11 US US13/140,272 patent/US8835614B2/en active Active
- 2009-12-11 ES ES19167964T patent/ES2937017T3/es active Active
- 2009-12-11 JP JP2011542288A patent/JP5658167B2/ja active Active
- 2009-12-11 EP EP22205652.5A patent/EP4212541A1/en active Pending
- 2009-12-11 SM SM20190375T patent/SMT201900375T1/it unknown
- 2009-12-11 SI SI200931981T patent/SI2889043T1/sl unknown
- 2009-12-11 PL PL12160009T patent/PL2465542T3/pl unknown
- 2009-12-11 BR BRPI0923047A patent/BRPI0923047B8/pt active IP Right Grant
- 2009-12-11 CN CN201610298866.4A patent/CN105879047A/zh active Pending
- 2009-12-11 ES ES14194176T patent/ES2735023T3/es active Active
- 2009-12-11 HU HUE19167964A patent/HUE060974T2/hu unknown
- 2009-12-11 SI SI200931162T patent/SI2465542T1/sl unknown
- 2009-12-11 EP EP19167964.6A patent/EP3608330B1/en active Active
- 2009-12-11 EP EP09771640A patent/EP2376123A2/en not_active Withdrawn
- 2009-12-11 MX MX2011006347A patent/MX2011006347A/es active IP Right Grant
- 2009-12-11 DK DK12160009.2T patent/DK2465542T3/en active
- 2009-12-11 CN CN2013103303923A patent/CN103432566A/zh not_active Withdrawn
- 2009-12-11 PT PT121600092T patent/PT2465542E/pt unknown
- 2009-12-11 DK DK19167964.6T patent/DK3608330T3/da active
- 2009-12-11 CA CA2747230A patent/CA2747230C/en not_active Expired - Fee Related
-
2011
- 2011-06-14 MX MX2019004905A patent/MX2019004905A/es unknown
- 2011-06-16 IL IL213595A patent/IL213595B/en active IP Right Grant
-
2014
- 2014-03-07 JP JP2014045356A patent/JP2014139204A/ja not_active Withdrawn
- 2014-07-29 US US14/445,941 patent/US9493498B2/en active Active
-
2015
- 2015-03-25 HR HRP20150340TT patent/HRP20150340T1/hr unknown
- 2015-03-25 IL IL237933A patent/IL237933A0/en unknown
- 2015-03-25 IL IL237932A patent/IL237932B/en active IP Right Grant
- 2015-03-30 SM SM201500082T patent/SMT201500082B/xx unknown
-
2016
- 2016-09-20 JP JP2016182748A patent/JP6659503B2/ja active Active
- 2016-10-07 US US15/288,486 patent/US10464962B2/en active Active
-
2019
- 2019-03-13 JP JP2019046041A patent/JP2019112444A/ja not_active Withdrawn
- 2019-06-18 HR HRP20191102TT patent/HRP20191102T1/hr unknown
- 2019-07-10 CY CY20191100730T patent/CY1121860T1/el unknown
- 2019-09-24 US US16/581,148 patent/US11279725B2/en active Active
- 2019-11-26 IL IL270930A patent/IL270930B/en unknown
-
2021
- 2021-06-20 IL IL284184A patent/IL284184B2/en unknown
- 2021-07-02 JP JP2021110649A patent/JP2021169467A/ja active Pending
-
2022
- 2022-02-14 US US17/671,249 patent/US12252504B2/en active Active
-
2023
- 2023-08-24 JP JP2023136066A patent/JP7590515B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150340T1 (hr) | Konjugati oligosaharid-protein | |
| JP2017008098A5 (enExample) | ||
| AR067181A1 (es) | Inhibidores de transcriptasa inversa de hiv, composicion farmaceutica, uso del compuesto para preparar un medicamento, agente de combinacion farmaceutica y metodo de inhibicion de la replicacion de un retrovirus | |
| MX2021015221A (es) | Compuestos de aminobenzazepina, inmunoconjugados y usos de estos. | |
| HUP9901296A2 (hu) | NMDA receptor antagonista hatású szubsztituált piridinszármazékok, valamint ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
| AR038843A1 (es) | Derivados de fenetanolamina para el tratamiento de enfermedades respiratorias | |
| ATE409048T1 (de) | Pharmazeutisch aktive oligosaccharid-conjugate | |
| JP2004506645A5 (enExample) | ||
| TW201004632A (en) | Compounds and pharmaceutical compositions for the treatment of viral infections | |
| MX2008012481A (es) | Derivado de glucopiranosida de fenilbencilo. | |
| NO20082635L (no) | Kjemisk blanding anvendelig som korrosjonsinhibitor | |
| AR103551A2 (es) | Composiciones que comprenden glifosato o una sal del mismo, un agente tensioactivo de un sacárido derivatizado y un agente tensioactivo de óxido de amina | |
| RU2010148562A (ru) | Композиции и способы для улучшения общего состояния зубов и улучшения их внешнего вида | |
| HRP20160222T1 (hr) | Biozaštite uporabom makrolida koji sadrže triazol | |
| AR048537A1 (es) | Derivados de nucleosidos para tratar infecciones por virus de hepatitis c. | |
| EA201171328A1 (ru) | Производное замещенного изохинолина | |
| IL293848A (en) | Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof | |
| RU2011144851A (ru) | Соли 6'-сиалиллактозы и способ их синтеза и синтеза других а-сиалилолигосахаридов | |
| MX2020011208A (es) | Composiciones de los o-glicosil flavonoides. | |
| ATE483444T1 (de) | Dentalzusammensetzung mit epoxy-funktionalen polymerisierbaren verbindungen | |
| RU2010101930A (ru) | Производные нистатина и их применение в качестве противогрипковых агентов | |
| MEP11608A (en) | Heparin-derived oligosaccharide mixtures, preparation thereof and pharmaceutical compositions containing said mixtures | |
| DK1315488T3 (da) | Farmaceutiske sammensætninger indeholdende aminothiazolderivater til behandling af motoriske funktionsforstyrrelser af tyktarm | |
| Hanessian et al. | Design and synthesis of mimics of S-adenosyl-L-homocysteine as potential inhibitors of erythromycin methyltransferases | |
| MX2012008389A (es) | Metodos para producir compuestos glicolipidos sustituidos con aminas. |